Get in touch!
Do you have a question for our technical experts? Or are you interested in learning more about our services and solutions? Please send us a message, and a member of our team will get back to you as soon as possible.
A global pioneer in improving breast cancer surgery, Endomag, has renewed a five-year manufacturing contract with ITL for the on-going production of its commercially successful surgical guidance system, the Sentimag® platform.
The Sentimag® platform helps surgeons mark, detect and accurately remove tumors or lymph nodes, causing minimal damage to the breast tissue. The technology works like a metal detector, which, when placed near the skin’s surface, can detect Endomag’s magnetic seed (Magseed®) or magnetic lymph node tracer (Magtrace®).
ITL successfully supported Endomag as it took the device from a proof of principle instrument to state-of-the-art medical technology. Endomag has won several awards for the design and production of the Sentimag® platform, including the Queen’s Award for Enterprise in Innovation in 2018.
Eric Mayes, CEO, Endomag, commented: “I am delighted to continue our relationship with the team at ITL. Their expertise in design, tooling, and manufacture has helped fulfill our technology’s potential as we strive to make cancer care better for patients everywhere. I am looking forward to continuing to work together, as we grow to meet global demand for the Sentimag® system.”
ITL manufactures the platform in Britain for use all around the world. To this day, the Sentimag® system is the world’s most sensitive handheld magnetic probe, used in 130,000+ breast cancer procedures across 550+ hospitals in more than 40 countries.
Tom Cole, Managing Director, said: “From humble beginnings as a spin-out from UCL to now being one of our longest-standing customers, it has been an absolute pleasure to work alongside Eric and the team as they’ve grown from strength to strength. We’re delighted to secure another five years of manufacturing with Endomag. They are a fantastic company to work alongside, and we greatly value the opportunity to work with them long term as they strive to improve the global standard of cancer care.”